Exeporfinium chloride

Drug Profile

Exeporfinium chloride

Alternative Names: XF-73

Latest Information Update: 07 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Destiny Pharma
  • Class Antibacterials; Porphyrins; Small molecules
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Staphylococcal infections

Most Recent Events

  • 05 Sep 2016 Efficacy data from a phase I/II trial in Staphylococcal infections released by Destiny Pharma
  • 01 Apr 2016 Destiny Pharma completes a phase I/II trial in Staphylococcal infections in USA (Intranasal) (NCT01592214)
  • 11 Nov 2015 Exeporfinium chloride receives Qualified Infectious Disease Product status for Staphylococcal infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top